Compare HCA Health Inc (HCA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Nomura Holdings Inc — how do they compare? HCA Health Inc trades at $411.34 (market cap $89.08B), while Nomura Holdings Inc trades at $9.94 (market cap $28.46B). The key difference: HCA Health Inc is far larger — about 3.1× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| HCA | NMR | |
|---|---|---|
Market Cap | $89.08B | $28.46B |
Sector | Health | Financials |
52-Week High | $545.13 | $10.04 |
52-Week Low | $361.32 | $6.73 |
Enterprise Value | $139.62B | — |
Dividend Yield | 0.76% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Nomura Holdings (NMR) trades at $9.82, down 1.31% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a robust net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst sentiment is mixed, with a 'Hold' consensus but positive momentum coverage in financial media.
The outlook for NMR is supported by fundamental strength in profitability and revenue expansion, though cash flow volatility and rising debt-to-asset ratios pose risks. The stock presents a value opportunity with a P/E of 11.59, but investors should weigh consistent earnings performance against macroeconomic and sector-specific headwinds affecting financial stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
